Compile Data Set for Download or QSAR
Report error Found 3459 Enz. Inhib. hit(s) with Target = 'DNA-dependent protein kinase catalytic subunit'
TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM766209(9-(4-hydroxybicyclo[2.2.1]heptan-1-yl)-7-methyl-2-...)
Affinity DataIC50: 0.0700nMAssay Description:Reagent: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM413448(US10407446, Example 1 | 9-((1r,4r)-4-hydroxycycloh...)
Affinity DataIC50: 0.0794nMAssay Description:Inhibition of human HeLa cell-derived full length DNA-PK catalytic subunit using fluorescein-EPPLSQEAFADLWKK as substrate preincubated for 30 mins fo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM50599238(CHEMBL5181303 | US11884671, Example 29)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648243(US11884671, Example 20)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648233(US11884671, Example 13 | US11884671, Example 10)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648224(US11884671, Example 1)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648244(US11884671, Example 21)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM50641425(CHEMBL5563688)
Affinity DataIC50: 0.100nMAssay Description:Inhibition of human DNA-PK incubated for 30 mins in presence of Mg/ATP by HTRF methodMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/12/2025
Entry Details
PubMed
TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648235(US11884671, Example 12)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648226(US11884671, Example 3)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM50641423(CHEMBL5566630)
Affinity DataIC50: 0.100nMAssay Description:Inhibition of human DNA-PK incubated for 30 mins in presence of Mg/ATP by HTRF methodMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/12/2025
Entry Details
PubMed
TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648250(US11884671, Example 27)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM413448(US10407446, Example 1 | 9-((1r,4r)-4-hydroxycycloh...)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648240(US11884671, Example 17)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM50599238(CHEMBL5181303 | US11884671, Example 29)
Affinity DataIC50: 0.100nMAssay Description:Inhibition of DNA-PK (unknown origin) using EPPLSQEAFADLWKK peptide as substrate preincubated with compound for 30 mins followed by substrate additio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/23/2023
Entry Details
PubMed
TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648231(US11884671, Example 8)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM50599239(CHEMBL5184141 | US11884671, Example 32)
Affinity DataIC50: 0.100nMAssay Description:Inhibition of DNA-PK (unknown origin) using EPPLSQEAFADLWKK peptide as substrate preincubated with compound for 30 mins followed by substrate additio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/23/2023
Entry Details
PubMed
TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648251(US11884671, Example 28)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648232(US11884671, Example 9)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648229(US11884671, Example 6)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648238(US11884671, Example 15)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648258(US11884671, Example 35)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648257(US11884671, Example 34)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648239(US11884671, Example 16)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648230(US11884671, Example 7)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648237(US11884671, Example 14)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648274(US11884671, Example 51)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM50599239(CHEMBL5184141 | US11884671, Example 32)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM50644065(CHEMBL5570653)
Affinity DataIC50: 0.110nMAssay Description:Inhibition of human full-length DNA-PK using EPPLSQEAFADLWKK as substrate incubated for 60 mins in presence of ATP by ADP-Glo kinase assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/12/2025
Entry Details
PubMed
TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM50599237(CHEMBL5180090 | US11884671, Example 30)
Affinity DataIC50: 0.120nMAssay Description:Inhibition of DNA-PK (unknown origin) using EPPLSQEAFADLWKK peptide as substrate preincubated with compound for 30 mins followed by substrate additio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/23/2023
Entry Details
PubMed
TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM50599240(CHEMBL5194436 | US11884671, Example 31)
Affinity DataIC50: 0.126nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM50599237(CHEMBL5180090 | US11884671, Example 30)
Affinity DataIC50: 0.126nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM50599240(CHEMBL5194436 | US11884671, Example 31)
Affinity DataIC50: 0.130nMAssay Description:Inhibition of DNA-PK (unknown origin) using EPPLSQEAFADLWKK peptide as substrate preincubated with compound for 30 mins followed by substrate additio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/23/2023
Entry Details
PubMed
TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648245(US11884671, Example 22)
Affinity DataIC50: 0.158nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648234(US11884671, Example 11)
Affinity DataIC50: 0.158nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648249(US11884671, Example 26)
Affinity DataIC50: 0.158nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM413460(US10407446, Example 13 | 9-cyclohexyl-7-methyl-2-(...)
Affinity DataIC50: 0.158nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648242(US11884671, Example 19)
Affinity DataIC50: 0.158nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM413449(US10407446, Example 2 | 9-((1s,4s)-4-hydroxycycloh...)
Affinity DataIC50: 0.158nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648225(US11884671, Example 2)
Affinity DataIC50: 0.158nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM413454(US10407446, Example 7 | (S)-7-methyl-2-((7-methyl-...)
Affinity DataIC50: 0.158nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM413460(US10407446, Example 13 | 9-cyclohexyl-7-methyl-2-(...)
Affinity DataIC50: 0.158nMAssay Description:Inhibition of human HeLa cell-derived full length DNA-PK catalytic subunit using fluorescein-EPPLSQEAFADLWKK as substrate preincubated for 30 mins fo...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM50526936(CHEMBL4450232)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of human HeLa cell-derived full length DNA-PK catalytic subunit using fluorescein-EPPLSQEAFADLWKK as substrate preincubated for 30 mins fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648233(US11884671, Example 13 | US11884671, Example 10)
Affinity DataIC50: 0.200nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM413459(US10407446, Example 12 | 9-((1s,4s)-4-hydroxy-1-me...)
Affinity DataIC50: 0.200nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648259(US11884671, Example 36)
Affinity DataIC50: 0.200nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM50641424(CHEMBL5591635)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of human DNA-PK incubated for 30 mins in presence of Mg/ATP by HTRF methodMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/12/2025
Entry Details
PubMed
TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648248(US11884671, Example 25)
Affinity DataIC50: 0.200nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM413453(US10407446, Example 6 | 9-((1r,4r)-methoxycyclohex...)
Affinity DataIC50: 0.251nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Juno Therapeutics

US Patent
LigandPNGBDBM648241(US11884671, Example 18)
Affinity DataIC50: 0.251nMAssay Description:The inhibitory activity of compounds against DNAPK was determined by TR-FRET measuring a fluorescent labelled peptide substrate converting to a phosp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2024
Entry Details
US Patent

Displayed 1 to 50 (of 3459 total ) | Next | Last >>
Jump to: